Companies › SLN

SILENCE THERAPEUTICS PLC (SLN)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001479615 · EDGAR filings · Updated 2026-07-16

SILENCE THERAPEUTICS PLC (SLN) has reported institutional ownership of 14.1%, with 56 institutional managers holding positions valued at $102.1M per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Latest updates

• 2026-07-16 — Amended current report (8-K/A) filed
• 2026-07-08 — SCHEDULE 13D/A filed
• 2026-07-07 — Insider transaction reported (Form 4)
• 2026-06-23 — Current report (8-K) filed
• 2026-06-16 — Current report (8-K) filed
• 2026-06-11 — Current report (8-K) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, SILENCE THERAPEUTICS PLC has 56 institutional holders and institutional ownership of 14.1%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 1 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Related companies

Kalaris Therapeutics Inc (KLRS) · PRELUDE THERAPEUTICS INC (PRLD) · ELECTROMED INC (ELMD) · ZENTALIS PHARMACEUTICALS INC (ZNTL) · COHERUS ONCOLOGY INC (CHRS) · FENNEC PHARMACEUTICALS INC (FENC)